Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So I'm here today with Doctor Elizabeth Buchbinder and we are going to be talking about the latest research in skin cancer and Melanomas. Uh Doctor Bookbinder, uh could you maybe give us a little bit of an introduction to your research interests and your clinical practice? Sure, absolutely. So I'm, I'm Beth Bookbinder, Medina Farber Cancer in student Boston. And I am entirely a Melanoma physician. So I treat Melanoma. I do research in Melanoma. I do a lot of work in the early drug development as well, suggesting new drugs in Melanoma, but also have a lot of interest kind of along the spectrum. So, in terms of immunotherapy and Melanoma targeted therapy, Melanoma also refining Melanoma therapies um and looking at outcomes for patients' kind of down the line including some survivorship work. So kind of run the gamut but really focused on Melanoma uh in particular. Great. And it's, it's really exciting to have this conversation today. We're going to be talking a little bit about Asco 2023. I'd love to hear from your perspective. What were the exciting topics, the hot topics that everyone was talking about with regards to Melanoma? Uh Oscar 2023. Yeah. So I think there are quite a few, I would say three or four really hot topics in Melanoma right now. And so I'll start with one of the early stage ones, which is the MRNA vaccines or as, as they're kind of becoming more named the, um, individualized therapy because what they're doing is taking the neo neo antigens, basically figuring out what the new antigens are on Toomer's and then creating an Mrna targeted therapy that then reacts allows the immune system to kind of get to know those antigens and react against them. Um And so there's really nice data in the adjuvant space. So in the preventative space combined with pembrolizumab demonstrating that uh it can lower relapse free survival. So there's tons of excitement in that space and looking at different kind of um um any gene products that train the immune system. So a bit like vaccines but kind of different cause they're not going to be universal, they're really individualized. And so um looking at these sorts of products and so that's one area that's incredibly exciting right now, some really nice data from Moderna and Merck looking at that and there's gonna be phase three trials coming. So a lot of buzz around that space. The second space I think there's been, there was a lot of excitement um at ASCO is around the lag three targeting space. So both with real until a mob as well as Uh And I can never say it feels like mob. So a new drug targeting lag three, there's been some, some real exciting data both. Um So on the, with the realtor LaMotte basically a revision two years worth of data um from that trial really demonstrating continued um benefit in terms of progression free survival and overall survival. Um which is very exciting for Melanoma in the front line. Um And then with the Fianna LaMotte data, basically demonstrating some nice responses. And so another potential agent to be investigated going forward. Um So those were kind of the big areas there. Um the third area where I think there was some some real excitement at Asco and not so much in terms of uh presentations, but just buzz in the background is with cellular therapy. Um As we're hoping maybe for uh approval of some till therapy products in the future. And so just kind of buzz around that there was uh discussion, although not so much abstracts at this particular meeting. And then the final area which actually um really is exploding in Melanoma is the neoadjuvant space. So the use of these drugs earlier earlier in the treatment of Melanoma. So before surgery, um and there, there were some nice presentations, there's actually a clinical um science's and posey um about neoadjuvant therapy that included some of the work being done in Melanoma. And I think that's a space where not only are we seeing benefit of neoadjuvant therapy and giving immunotherapy before surgery. But there's also a very, very active effort to figure out how to tailor that. What is the best therapy in that space? Um And what is the best time can we change surgery based upon responses to new adjuvant therapy? Um, what other markers can we follow things like CTDN A and other things to figure out how we determine how much, how much therapy or surgery patient's need. And so that's a huge area that's kind of very, very active right now and that there are a lot of presentations around that at Asco Super Exciting. Uh There's lots going on in this space if you were to look at, ask you 2024 and between now and then some of the exciting work that's going on in, in Melanoma, what might we expect to see everyone talking about it and ask 2024? Yeah. So I think what we're likely to see is combinations moving into that neoadjuvant setting, you know, so we talked about lag three. There's some other interesting targets and interesting uh combinations with PD one inhibition that I think we'll be seeing in that neo adjuvant space. Hopefully allowing us to better figure out what are those best drugs to give up front before surgery? And then also can we use those to tailor surgery? So I think there'll be some really interesting data um in that space, you know, I think the other thing are going to be some novel combinations that we may see and then also a German data. So um a German data with like three a German data with some of these other successful combinations, I think we may be seeing more of that kind of into Asco 2024. And then who knows there also, you know, trials ongoing that surprise us and new exciting, you know, phase one drugs. I think the other space that kind of has gotten forgotten at Asco this year. But we're, we're seeing kind of some, some interesting data is the targeted therapy space and getting better at doing different sort of targeted therapy approaches. And maybe we'll see something there next year. Super exciting uh Doctor Bookbinders. Thank you so much for your time today. I'm really grateful for that really uh super overview of, of uh Melanoma is at uh 2023 and a little glimpse of what's going to be coming down the line. So, thank you so much for your time. Absolutely. Thank you.